Brokerage : Hana Securities
Analyst : Seona Kim (RA: Changkeun Yoo)
Investment Rating : BUY (Maintained)
Target Price : KRW 580,000 (Downgraded)
Core Momentum : Target price adjusted reflecting Keytruda SC’s economics in Merck’s Form 10-Q (USD 1B in sales milestones prior to receiving a 2% royalty) alongside calibrated future licensing milestone assumptions, with share price recovery anchored by the frequency and volume of new deals in 2026.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Maintained) / Target Price (12M) KRW 580,000 (Downgraded from KRW 640,000) (Closing price as of January 21, 2026: KRW 373,500)
- Valuation Methodology & Target Price Downgrade Rationale:
- Derived based on 2029E EBIT—the projected peak royalty inflection period within 5 years when the full USD 1 Billion Keytruda sales milestone is achieved and Keytruda SC sales reach USD 10 Billion—applying a WACC of 8.4%.
- Target Price Downgrade Drivers: Reflects both the reduction in 2025–2029 cumulative Keytruda licensing revenue estimates (from USD 1.5B to USD 940M) and the downward calibration of general single-product milestone assumptions (adjusted to USD 260M–280M), alongside adjustments to cash-inflow timing and biosimilar out-licensing scales.
- Market Data: KOSDAQ Index 951.29pt / Market Cap KRW 19.98 Trillion (Weight 3.84%) / Shares Outstanding 53,505,800 / 60-Day Average Trading Volume 685.6 Thousand Shares / 60-Day Average Trading Value KRW 32.40 Billion / Foreign Ownership 13.89% / 52-Week High KRW 559,000, Low KRW 317,500 / Major Shareholders: Soonjae Park and 4 affiliates 20.38%, Inwoo Hyung and 2 affiliates 5.09%
- Annual Financial Forecast (Hana Securities Estimates):
- 2025F: Revenue KRW 203.5 Billion (+97.8% YoY), Operating Profit KRW 101.6 Billion (+300.0% YoY, OPM 49.9%), Pre-tax Profit KRW 107.8 Billion, Net Profit KRW 83.9 Billion, EPS KRW 1,560 (+33.22% YoY), BPS KRW 7,167, PER 288.14x, PBR 62.72x, ROE 25.48%, EV/EBITDA 226.46x
- 2026F: Revenue KRW 469.8 Billion (+130.9% YoY), Operating Profit KRW 303.8 Billion (+199.0% YoY, OPM 64.7%), Pre-tax Profit KRW 302.2 Billion, Net Profit KRW 242.2 Billion, EPS KRW 4,491 (+187.88% YoY), BPS KRW 11,657, PER 83.17x, PBR 32.04x, ROE 47.84%, EV/EBITDA 63.72x
🚀 2. [Market Opportunities & Business Outlook]
- Clarification of Merck Keytruda Royalty Structure:
- Merck’s Form 10-Q disclosed the terms of the agreement: “After the achievement of all sales-based milestones, a 2% royalty on net sales is payable to Alteogen.”
- Under this framework, Alteogen receives up to USD 1.0 Billion in tiered sales milestones as specific revenue thresholds are reached, receiving no commercial royalties until the USD 1.0 Billion is fully recognized, after which a 2% royalty applies.
- While typical upfront payments range from USD 20M to USD 25M, Keytruda’s total contract value is substantially higher than assets like Enhertu or Jemperli.
- As contract terms vary by target, estimated royalty rates for non-Keytruda assets are maintained at 3.2% (based on Darzalex SC benchmarks).
- Financial Model Adjustments & Target Price Revision Drivers:
- Cumulative Keytruda licensing revenue estimates from 2025 to 2029 were revised down from USD 1.5 Billion to USD 940 Million.
- In conjunction with the Keytruda revision, general milestone sum assumptions for standard single-product contracts were calibrated to USD 260M–280M (compared to the earlier USD 580M reference from Imfinzi), and adjustments to cash inflow timing and biosimilar licensing volumes were directly factored into the target price reduction.
- Key Share Price Driver: Deal Frequency and Volume:
- Alteogen maintains peer-leading profitability, supported by a 12-month forward operating profit margin (OPM) of 69.7%.
- The analyst highlights the frequency and number of new out-licensing deals in 2026 as the most decisive drivers for share price recovery.
📝 Editor’s Comment (Perspective)
The analyst views the clarification of Keytruda SC’s contract structure in Merck’s Form 10-Q (receiving USD 1 Billion in sales milestones before transitioning to a 2% royalty), combined with downward adjustments to future single-product milestone assumptions (USD 260M–280M) and cash-inflow timing, as the core rationale for revising the target price to KRW 580,000. The overarching perspective prioritizes long-term cash generation anchored to 2029E EBIT (when Keytruda SC is projected to hit USD 10 Billion in annual sales) and the potential for multiple new licensing agreements starting in 2026 to catalyze valuation recovery over short-term sentiment shocks.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the frequency and contract terms of new licensing deals executed in 2026, the progress of tiered milestone inflows toward the USD 1 Billion Keytruda threshold, and the timeline of cash inflows from biosimilar partnerships and follow-on assets. These developments can be verified through upcoming quarterly earnings releases, official company IR presentations, regulatory filings on DART/KRX, and Merck’s (MSD) corporate disclosures.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
